JP2016512198A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512198A5 JP2016512198A5 JP2015561594A JP2015561594A JP2016512198A5 JP 2016512198 A5 JP2016512198 A5 JP 2016512198A5 JP 2015561594 A JP2015561594 A JP 2015561594A JP 2015561594 A JP2015561594 A JP 2015561594A JP 2016512198 A5 JP2016512198 A5 JP 2016512198A5
- Authority
- JP
- Japan
- Prior art keywords
- independently selected
- group
- optionally substituted
- hydrogen
- aliphatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 64
- 239000001257 hydrogen Substances 0.000 claims description 64
- 125000001931 aliphatic group Chemical group 0.000 claims description 46
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 44
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 44
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 44
- 125000005842 heteroatom Chemical group 0.000 claims description 44
- 229910052760 oxygen Inorganic materials 0.000 claims description 44
- 239000001301 oxygen Substances 0.000 claims description 44
- 229910052717 sulfur Inorganic materials 0.000 claims description 44
- 239000011593 sulfur Substances 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 23
- VVGPECAOVDZTLZ-UHFFFAOYSA-N [N]NC(N)=N Chemical compound [N]NC(N)=N VVGPECAOVDZTLZ-UHFFFAOYSA-N 0.000 claims description 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 206010048610 Cardiotoxicity Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 231100000259 cardiotoxicity Toxicity 0.000 claims description 2
- 150000003943 catecholamines Chemical class 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002651 drug therapy Methods 0.000 claims description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 208000014321 polymorphic ventricular tachycardia Diseases 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 238000001308 synthesis method Methods 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 206010047302 ventricular tachycardia Diseases 0.000 claims description 2
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 229940043709 CaM kinase II inhibitor Drugs 0.000 description 1
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 1
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361773779P | 2013-03-06 | 2013-03-06 | |
| US61/773,779 | 2013-03-06 | ||
| PCT/US2014/020700 WO2014138212A1 (en) | 2013-03-06 | 2014-03-05 | CaMKII INHIBITORS AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512198A JP2016512198A (ja) | 2016-04-25 |
| JP2016512198A5 true JP2016512198A5 (enExample) | 2017-04-06 |
| JP6318180B2 JP6318180B2 (ja) | 2018-04-25 |
Family
ID=51491905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561594A Active JP6318180B2 (ja) | 2013-03-06 | 2014-03-05 | ＣａＭＫＩＩ阻害剤及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9951061B2 (enExample) |
| EP (1) | EP2964225B1 (enExample) |
| JP (1) | JP6318180B2 (enExample) |
| CN (1) | CN105517549B (enExample) |
| AU (1) | AU2014225889B2 (enExample) |
| CA (1) | CA2901155C (enExample) |
| WO (1) | WO2014138212A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107074856A (zh) | 2014-09-05 | 2017-08-18 | 阿略斯泰罗斯医疗公司 | CaMKII抑制剂及其用途 |
| JP6532737B2 (ja) * | 2015-04-01 | 2019-06-19 | 東ソー・ファインケム株式会社 | ヘテロアセン化合物の製造方法 |
| AR110252A1 (es) * | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
| KR20200027521A (ko) * | 2017-07-06 | 2020-03-12 | 칠드런'즈 메디컬 센터 코포레이션 | 카테콜아민성 다형성 심실성 빈맥을 치료하거나 예방하기 위한 조성물 및 방법 |
| JP7500426B2 (ja) | 2018-02-21 | 2024-06-17 | ブリストル－マイヤーズ スクイブ カンパニー | Ｃａｍｋ２ｄアンチセンスオリゴヌクレオチドおよびその使用 |
| CN108904532B (zh) * | 2018-08-20 | 2021-07-27 | 上海市第一人民医院 | 一种富勒烯C60纳米晶体联合CaMKII抑制剂的组合物的应用 |
| WO2024197267A1 (en) * | 2023-03-22 | 2024-09-26 | The Regents Of The University Of Colorado, A Body Corporate | Inhibitors of ca 2+/calmodulin-dependent protein kinase ii (camkii) that do not inhibit long-term potentiation (ltp) induction and therapeutic uses thereof |
| TW202535878A (zh) * | 2023-11-07 | 2025-09-16 | 美商卡都瑞恩醫藥公司 | 吡啶基咪唑並［１，２－ｂ］嗒𠯤之多晶型物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6257798A (en) | 1997-01-31 | 1998-08-25 | Board Of Trustees Of The Leland Stanford Junior University | Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase |
| BR0213043A (pt) | 2001-10-01 | 2004-10-05 | Univ Vanderbilt | Métodos de tratar ou prevenir dusfunção contrátil miocárdica após infarto do miocárdio em um sujeito, de tratar ou prevenir cardiomiopatia dilatada em um sujeito e de incrementar contratilidade miocárdica em um sujeito, animal transgênico, e, método de identificar um composto que pode tratar doença estrutural do coração |
| WO2004058764A1 (en) * | 2002-12-27 | 2004-07-15 | Bayer Healthcare Ag | 4-phenyl-pyrimido [4,5-b] indole derivatives |
| WO2006007422A2 (en) * | 2004-06-16 | 2006-01-19 | The Trustees Fo Columbia University In The City Of New York | CaMKII/CALCIUM CHANNEL PHOSPHORYLATION-RELATED COMPOSITIONS AND METHODS |
| CN101052420A (zh) | 2004-11-02 | 2007-10-10 | 大日本住友制药株式会社 | 用于治疗自体免疫疾病的并用药 |
| BRPI0610828A2 (pt) * | 2005-05-16 | 2010-07-27 | Irm Llc | compostos e composições como inibidores de proteìna quinase |
| ES2380795T3 (es) * | 2005-05-20 | 2012-05-18 | Vertex Pharmaceuticals, Inc. | Pirrolopiridinas útiles como inhibidores de proteínas quinasas |
| JP2008542433A (ja) * | 2005-06-09 | 2008-11-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＣＤＫ−１インヒビターとしてのα−カルボリン |
| EP1979353A2 (en) * | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
| CL2008001540A1 (es) * | 2007-05-29 | 2009-05-22 | Sgx Pharmaceuticals Inc | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. |
| EP2161271A1 (en) * | 2008-09-08 | 2010-03-10 | Università Degli Studi Di Milano - Bicocca | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl |
| US8440656B2 (en) | 2009-06-22 | 2013-05-14 | University Of Iowa Research Foundation | Methods of treating pulmonary diseases and disorders by modulating calcium/calmodulin dependent protein kinase II activity |
| EP2582668B1 (en) * | 2010-06-16 | 2016-01-13 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
-
2014
- 2014-03-05 WO PCT/US2014/020700 patent/WO2014138212A1/en not_active Ceased
- 2014-03-05 CN CN201480012869.6A patent/CN105517549B/zh active Active
- 2014-03-05 JP JP2015561594A patent/JP6318180B2/ja active Active
- 2014-03-05 CA CA2901155A patent/CA2901155C/en active Active
- 2014-03-05 AU AU2014225889A patent/AU2014225889B2/en not_active Ceased
- 2014-03-05 US US14/773,308 patent/US9951061B2/en active Active
- 2014-03-05 EP EP14760472.2A patent/EP2964225B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512198A5 (enExample) | ||
| PH12018550049A1 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
| ES2702541T3 (es) | Pamoato de donepezilo, método de preparación y su uso | |
| JP2013010792A5 (enExample) | ||
| JP2017534572A5 (enExample) | ||
| JP2016538257A5 (enExample) | ||
| JP2013545730A5 (enExample) | ||
| WO2015191506A3 (en) | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles | |
| HU226138B1 (en) | R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof | |
| JP2019524897A5 (enExample) | ||
| JP2010511701A5 (enExample) | ||
| JP2013540114A5 (enExample) | ||
| CY1109370T1 (el) | Παραγωγα οξαδιαζολονης ως ppar δελτα αγωνιστες | |
| CN102497864A (zh) | 用于预防或治疗由化疗诱发的疼痛的σ配体 | |
| JP2011518168A5 (enExample) | ||
| JP2022523702A (ja) | トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法 | |
| CO6341628A2 (es) | \\\\\\\"nuevos compuestos adecuados como precursores de compuestos que son utiles para obtener imegenes de depositos amiloides\\\\\\\" | |
| KR20120099212A (ko) | 트라마돌 및 콕시브의 공결정 | |
| ES2924728T3 (es) | Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas | |
| JP2015522592A5 (enExample) | ||
| JP2014532751A5 (enExample) | ||
| JP2015515496A5 (enExample) | ||
| RU2013107659A (ru) | ИНГИБИТОР КАЗЕИНКИНАЗЫ 1δ И КАЗЕИНКИНАЗЫ 1ε | |
| JP5960695B2 (ja) | パンテニルドコサヘキサエノアート、ならびに心血管疾患を治療および予防するためのその使用 | |
| JP4964593B2 (ja) | 神経学的病状の治療用のテトラヒドロインドロン誘導体 |